Literature DB >> 10772996

Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia.

J M Binley1, B Clas, A Gettie, M Vesanen, D C Montefiori, L Sawyer, J Booth, M Lewis, P A Marx, S Bonhoeffer, J P Moore.   

Abstract

Antibody responses are often considered to play only a limited role in controlling viremia during chronic infections with human or simian immunodeficiency virus (SIV). We investigated this by determining the effect of passively infused antibody on plasma viremia in infected rhesus macaques. The emphasis of the study was to understand the mechanism(s) underlying any observed effects. We infused serum immunoglobulins (SIVIG) purified from SIV(mac)251-infected macaques into other SIV(mac)251-infected macaques. The rapid progressor recipients had high viral loads but negligible titers of antibodies to SIV. Thus, we could significantly increase antibody titers with exogenous SIVIG. Despite restoring anti-SIV titers to levels typical of macaques with a normal disease course, SIVIG had only a modest effect on plasma SIV RNA and cell-associated viral load; the maximum, transient, reduction was threefold. The decrease in plasma RNA commenced within 1-2 h of SIVIG infusion, the nadir was at 12 h, and then a rebound occurred. A two- to threefold drop in cell-associated viral RNA was simultaneous with the decrease in plasma RNA. The kinetics of the viremia changes are inconsistent with neutralization of new cycles of infection. More likely, perhaps unexpectedly, is that infused antibodies killed SIV-infected cells, via an effector mechanism such as antibody-dependent cellular cytotoxicity. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772996     DOI: 10.1006/viro.2000.0254

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

4.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Authors:  Donald N Forthal; Gary Landucci; Tran B Phan; Juan Becerra
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  James M Binley; Rogier W Sanders; Aditi Master; Charmagne S Cayanan; Cheryl L Wiley; Linnea Schiffner; Bruce Travis; Shawn Kuhmann; Dennis R Burton; Shiu-Lok Hu; William C Olson; John P Moore
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 8.  Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Authors:  Yi Xiao; Xiaonan Dong; Ying-Hua Chen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

9.  Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Authors:  Nancy L Haigwood; David C Montefiori; William F Sutton; Janela McClure; Andrew J Watson; Gerald Voss; Vanessa M Hirsch; Barbra A Richardson; Norman L Letvin; Shiu-Lok Hu; Philip R Johnson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

Authors:  Jeffrey M Jacobson; Robert J Israel; Israel Lowy; Nancy A Ostrow; Linda S Vassilatos; Melanie Barish; Diep N H Tran; Brian M Sullivan; Thomas J Ketas; Tobias J O'Neill; Kirsten A Nagashima; Wei Huang; Christos J Petropoulos; John P Moore; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.